← All trials
NCT06482268
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2024
- Primary completion
- Feb 28, 2025
- Completion date
- May 31, 2028
- First posted
- Jul 1, 2024
- Last posted
- Oct 30, 2024
- Enrollment
- 7
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San DiegoLead sponsor
- University of California, San DiegoSponsor investigator
- Sumitomo DainipponCollaborator
- SumitomoCollaborator
- Kyoto UniversityCollaborator
- University of California, San DiegoOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.